AEON Biopharma Strikes Debt-for-Equity Deal With Daewoong
I'm PortAI, I can summarize articles.
AEON Biopharma Inc. has entered into a debt-for-equity deal with Daewoong Pharmaceutical, converting $15 million of convertible notes into new equity, $1.5 million of new notes due in 2030, and a warrant for 8 million shares. The transaction aims to eliminate over 90% of AEON's debt and strengthen their strategic relationship. Shareholder approval is pending.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments